Goldman Sachs
KYMR icon

Goldman Sachs’s Kymera Therapeutics KYMR Stock Holding History

Goldman Sachs’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136M Buy
1,187,333
+298,924
+34% +$25.7M 0.01% 991
2026
Q1 		$74M Buy
888,409
+148,103
+20% +$11.7M 0.01% 1259
2025
Q4 		$57.6M Buy
740,306
+28,862
+4% +$1.95M 0.01% 1396
2025
Q3 		$40.3M Buy
711,444
+432,708
+155% +$19.5M ﹤0.01% 1610
2025
Q2 		$12.2M Sell
278,736
-65,501
-19% -$2.26M ﹤0.01% 2587
2025
Q1 		$9.42M Sell
344,237
-89,707
-21% -$3.27M ﹤0.01% 2750
2024
Q4 		$17.5M Buy
433,944
+209,113
+93% +$9.44M ﹤0.01% 2266
2024
Q3 		$10.6M Sell
224,831
-237,478
-51% -$10.5M ﹤0.01% 2644
2024
Q2 		$13.8M Buy
462,309
+11,791
+3% +$408K ﹤0.01% 2196
2024
Q1 		$18.1M Sell
450,518
-224,137
-33% -$8.02M ﹤0.01% 1935
2023
Q4 		$17.2M Buy
674,655
+469,947
+230% +$8.4M ﹤0.01% 2044
2023
Q3 		$2.85M Sell
204,708
-136,837
-40% -$2.75M ﹤0.01% 3478
2023
Q2 		$7.85M Buy
341,545
+44,702
+15% +$1.28M ﹤0.01% 2685
2023
Q1 		$8.8M Sell
296,843
-41,087
-12% -$1.33M ﹤0.01% 2537
2022
Q4 		$8.43M Buy
337,930
+1,171
+0.3% +$31.2K ﹤0.01% 2724
2022
Q3 		$7.33M Buy
336,759
+59,495
+21% +$1.57M ﹤0.01% 2800
2022
Q2 		$5.46M Buy
277,264
+33,338
+14% +$779K ﹤0.01% 3057
2022
Q1 		$10.3M Sell
243,926
-23,864
-9% -$1.01M ﹤0.01% 2664
2021
Q4 		$17M Buy
267,790
+87,583
+49% +$5.1M ﹤0.01% 2277
2021
Q3 		$10.6M Buy
180,207
+100,204
+125% +$5.81M ﹤0.01% 2671
2021
Q2 		$3.88M Buy
80,003
+65,507
+452% +$2.84M ﹤0.01% 3576
2021
Q1 		$563K Sell
14,496
-13,434
-48% -$809K ﹤0.01% 5032
2020
Q4 		$1.73M Sell
27,930
-119,808
-81% -$5.84M ﹤0.01% 3825
2020
Q3 		$4.77M Buy
+147,738
New +$4.51M ﹤0.01% 2942

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Goldman Sachs's KYMR Position: Q2 2026 in Review

Goldman Sachs increased its Kymera Therapeutics (KYMR) stake by 34% in Q2 2026, buying an estimated $25.7M and bringing the position to 1,187,333 shares worth $136M. The position accounts for 0.01% of the portfolio, ranked #991.

Goldman Sachs first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Goldman Sachs held 1,187,333 shares of Kymera Therapeutics worth $136M as of Q2 2026.
  • Goldman Sachs bought 298,924 Kymera Therapeutics shares in Q2 2026, an estimated $25.7M.
  • Kymera Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #991 holding.
  • Goldman Sachs first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.